scholarly journals Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2

2015 ◽  
pp. 2577
Author(s):  
Rongcheng Luo ◽  
Yifen Wu ◽  
Rong Li ◽  
Junyi Zhang ◽  
Gang Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Protein Tyrosine Phosphatase ◽  
Breast Cancer Cells ◽  
Tyrosine Phosphatase ◽  
Protein Tyrosine ◽  
Her 2 ◽  
Positive Breast Cancer

scholarly journals Focal adhesion kinase regulates the phosphorylation protein tyrosine phosphatase-α at Tyr789 in breast cancer cells

2015 ◽  
Vol 11 (6) ◽  
pp. 4303-4308 ◽  
Author(s):  
XU-QIAN FANG ◽  
XIANG-FAN LIU ◽  
LING YAO ◽  
CHANG-QIANG CHEN ◽  
JIA-FEI LIN ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Focal Adhesion Kinase ◽  
Cancer Cells ◽  
Focal Adhesion ◽  
Protein Tyrosine Phosphatase ◽  
Breast Cancer Cells ◽  
Tyrosine Phosphatase ◽  
Protein Tyrosine

scholarly journals Protein-tyrosine Phosphatase PTPL1/FAP-1 Triggers Apoptosis in Human Breast Cancer Cells

2002 ◽  
Vol 277 (49) ◽  
pp. 47861-47869 ◽  
Author(s):  
Guillaume Bompard ◽  
Carole Puech ◽  
Christine Prébois ◽  
Françoise Vignon ◽  
Gilles Freiss
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Protein Tyrosine Phosphatase ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Tyrosine Phosphatase ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Protein Tyrosine

Integrative genome wide analysis of protein tyrosine phosphatases identifies CDC25C as prognostic and predictive marker for chemoresistance in breast cancer

2021 ◽  
pp. 1-14
Author(s):  
Rachel Topno ◽  
Nazia Nazam ◽  
Pallawi Kumari ◽  
Manoj Kumar ◽  
Pallavi Agarwal
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Protein Tyrosine Phosphatase ◽  
Breast Cancer Cells ◽  
Tyrosine Phosphatase ◽  
Expression Patterns ◽  
Prognostic Index ◽  
Predictive Marker ◽  
Protein Tyrosine

BACKGROUND: The breast cancer subtype deficient in estrogen receptor and human epidermal growth factor receptor-2 (ER-/HER2-) displays enhanced aggressiveness, metastasis and disease relapse due to chemoresistance. ER-/HER2- patients lack molecularly targeted treatment hence, new therapeutic and prognostic biomarkers are required for better patient management. OBJECTIVES: To investigate the prognostic role of protein tyrosine phosphatase genes in Breast Cancer and their relevance as predictive markers for chemoresistance. METHODS: We examined the expression of 114 protein tyrosine phosphatase (PTP) genes in 1700 breast cancer patient’s tumor samples with respect to ER-/HER2- subtype. Correlation of relevant candidates with chemoresistance was analyzed in breast cancer cells resistant to taxane/anthracycline based drugs. The prognostic value of key candidates was assessed using Kaplan Meier plots and Nottingham prognostic index and expression pattern was confirmed using qRT-PCR. The epigenetic regulation was analyzed using ChIP-Seq datasets. By plotting ROC plots, clinical outcome after treatment with taxane and anthracycline was established. RESULTS: Overexpression of CDC25A and CDC25C and under-expression of DUSP16 was observed in tumor samples of ER-/HER2- patients and breast cancer cells. Similar expression patterns of these candidate genes were observed in MCF7 cells resistant to paclitaxel and adriamycin and also correlated with poor prognosis of breast cancer patients. Increased CDC25A and CDC25C in ER-/HER2- cells was found to be regulated epigenetically by histone H3K4 methylation. Overall, the present study establishes increased expression of protein tyrosine phosphatase CDC25C as a poor prognostic marker for breast cancer. CONCLUSION: Our study highlights the role of CDC25C in chemoresistance to taxane and anthracycline based therapy and proposes CDC25C as a potential predictive marker for these cancer therapies.

scholarly journals Estrogens and PTP1B Function in a Novel Pathway to Regulate Aromatase Enzymatic Activity in Breast Cancer Cells

Endocrinology ◽  
2012 ◽  
Vol 153 (11) ◽  
pp. 5157-5166 ◽  
Author(s):  
Ines Barone ◽  
Cinzia Giordano ◽  
Rocco Malivindi ◽  
Marilena Lanzino ◽  
Pietro Rizza ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Enzymatic Activity ◽  
Cancer Cells ◽  
Tyrosine Phosphorylation ◽  
Protein Tyrosine Phosphatase ◽  
Breast Cancer Cells ◽  
Tyrosine Phosphatase ◽  
Aromatase Activity ◽  
Phosphatidylinositol 3 Kinase ◽  
Protein Tyrosine

Abstract Local estrogen production by aromatase is an important mechanism of autocrine stimulation in hormone-dependent breast cancer. We have previously shown that 17-β estradiol (E2) rapidly enhances aromatase enzymatic activity through an increase of tyrosine protein phosphorylation controlled by the activity of the c-Src kinase in breast cancer cells. Here, we investigated the protein tyrosine phosphatase PTP1B (protein tyrosine phosphatase 1B) as a potential regulator of aromatase activity. We demonstrated a specific association between PTP1B and aromatase at protein-protein level and a reduction of aromatase activity in basal and E2-treated MCF-7 and ZR75 breast cancer cells when PTP1B was overexpressed. Indeed, a specific tyrosine phosphatase inhibitor increased basal and E2-induced enzymatic activity as well as tyrosine phosphorylation status of the purified aromatase protein. Moreover, E2 through phosphatidylinositol 3 kinase/Akt activation caused a significant decrease of PTP1B catalytic activity along with an increase in its serine phosphorylation. Concomitantly, the phosphatidylinositol 3 kinase inhibitor LY294002 or a dominant negative of Akt was able to reduce the E2 stimulatory effects on activity and tyrosine phosphorylation levels of aromatase. Taken together, our results suggest that E2 can impair PTP1B ability to dephosphorylate aromatase, and thus it increases its enzymatic activity, creating a positive feedback mechanism for estradiol signaling in breast cancer.

Sign in / Sign up

Export Citation Format

Share Document